Optimisation of the Anti-Trypanosoma brucei Activity of the Opioid Agonist U50488
作者:Victoria C. Smith、Laura A. T. Cleghorn、Andrew Woodland、Daniel Spinks、Irene Hallyburton、Iain T. Collie、N. Yi Mok、Suzanne Norval、Ruth Brenk、Alan H. Fairlamb、Julie A. Frearson、Kevin D. Read、Ian H. Gilbert、Paul G. Wyatt
DOI:10.1002/cmdc.201100278
日期:2011.10.4
Active Compounds (LOPAC) against cultured Trypanosoma brucei, the causative agent of African sleeping sickness, resulted in the identification of a number of compounds with selective antiproliferative activity over mammalian cells. These included (+)‐(1R,2R)‐U50488, a weak opioid agonist with an EC50 value of 59 nM as determined in our T. brucei in vitro assay reported previously. This paper describes
针对培养的布氏锥虫(非洲昏睡病的病原体)筛选 Sigma-Aldrich 药理活性化合物库 (LOPAC) ,鉴定出许多对哺乳动物细胞具有选择性抗增殖活性的化合物。其中包括 (+)-(1 R ,2 R )-U50488,这是一种弱阿片类激动剂,EC 50值为 59 n M,如我们之前报道的布氏锥虫体外试验所测定。本文描述了对 U50488 关键结构元素的修饰,以研究结构-活性关系 (SAR) 并优化该化合物的抗增殖活性和药代动力学特性。